State Street Corp. Discloses Passive Stake in Crinetics Pharma
Ticker: CRNX · Form: SC 13G · Filed: Jan 24, 2024 · CIK: 1658247
| Field | Detail |
|---|---|
| Company | Crinetics Pharmaceuticals, Inc. (CRNX) |
| Form Type | SC 13G |
| Filed Date | Jan 24, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, form-13g
TL;DR
**State Street just revealed a big, passive stake in Crinetics Pharma, signaling institutional confidence.**
AI Summary
State Street Corporation, a major financial institution, reported on January 24, 2024, that it holds a significant stake in Crinetics Pharmaceuticals, Inc. (CRNX) as of December 31, 2023. This filing indicates State Street's passive ownership of Crinetics' common stock, signaling their belief in the company's long-term prospects without seeking to influence management. For investors, this means a large, reputable institution sees value in Crinetics, potentially adding a layer of confidence to the stock.
Why It Matters
This filing shows a major institutional investor, State Street Corporation, has a significant, passive stake in Crinetics Pharmaceuticals, which can be seen as a vote of confidence in the company's future.
Risk Assessment
Risk Level: low — This filing indicates a passive investment by a large institution, which generally reduces perceived risk for other investors.
Analyst Insight
A smart investor would note State Street's passive stake as a potential positive signal, but also understand that a passive stake doesn't imply active management involvement or a change in company strategy. Further research into Crinetics' fundamentals and State Street's overall investment strategy would be prudent.
Key Players & Entities
- State Street Corporation (company) — the reporting person and institutional investor
- Crinetics Pharmaceuticals, Inc. (company) — the subject company whose common stock is being reported
- 0000093751-24-000143 (person) — accession number for the filing
- 20240124 (person) — date of filing
- 12/31/2023 (person) — date of event requiring the filing
- 22663K107 (person) — CUSIP number for Crinetics Pharmaceuticals common stock
FAQ
Who filed this SC 13G statement?
The SC 13G statement was filed by State Street Corporation, as indicated in the 'FILED BY' section and 'NAME OF REPORTING PERSON' on page 2.
What is the subject company of this filing?
The subject company is Crinetics Pharmaceuticals, Inc., as stated under 'SUBJECT COMPANY' and 'NAME OF ISSUER' on page 1.
What type of securities are covered by this filing?
The filing covers 'COMMON STOCK' of Crinetics Pharmaceuticals, Inc., as specified under 'TITLE OF CLASS OF SECURITIES' on page 1.
What was the date of the event that triggered this filing?
The date of the event which required the filing of this statement was December 31, 2023, as noted on page 1 under 'DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT'.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13D-1 (B), indicated by the 'X' next to 'RULE 13D-1 (B)' on page 1.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 24, 2024 by 0000093751-24-000143 regarding Crinetics Pharmaceuticals, Inc. (CRNX).